Home - Biat Group

Accelerate Drug Development Safely: The Power of Dose Range Finding and Zebrafish in Preclinical Research

Discover how the Dose Range Finding (DRF) assay and zebrafish as an alternative model are revolutionizing preclinical research. Learn how DRF determines compound tolerability levels and why zebrafish, with their genetic similarity to humans, transparency, and cost-effectiveness, are invaluable in toxicity screening. Find out how this approach saves time and costs in early drug discovery while ensuring drug safety. Speed up your research with zebrafish and unlock the potential of faster, safer drug development.

June 23, 2023 No Comments

ZIP SOLUTIONS AND RESEARCHER MIGUEL ÁNGEL MORENO-MATEOS INITIATE SCIENTIFIC ALLIANCE TO BOOST PRECISION GENE EDITING

Barcelona, Seville (June, 15)– Zip Solutions (Biat Group, ticker BST) and Dr. Miguel Ángel Moreno-Mateos have entered into a strategic collaboration to advance the optimisation of precision gene editing. Gene editing is a revolutionary technology that allows us to make precise changes to DNA, the

June 15, 2023 No Comments

“Split-Inteins Show Potential for Overcoming Gene Therapy Limitations in Muscular Dystrophy Treatment”

Researchers from the University of Washington and University Hospital Heidelberg have developed new research advances in the treatment of muscular dystrophy using split intein-mediated protein trans-splicing, that allow for the production of functional dystrophin proteins in vitro and in vivo. Muscular dystrophy is a genetic

June 9, 2023 No Comments

ZIP Solutions and YIMA Announce Strategic Co-Marketing Agreement for Gene Therapy

May , 2023 – Barcelona, Spain and Shenzhen, China – ZIP Solutions (Barcelona), a 100% affiliate of Biat Group (ticker BST), and YIMA, a Cyagen-owned AI-enabled biotech company, are pleased to announce a strategic co-marketing agreement for gene therapy. Under the agreement, ZIP Solutions will

June 6, 2023 No Comments

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	11 months	Cookie from Google Inc. to collect web statistics. No personal user data is collected.
_ga_********	11 months	Cookie from Google Inc. to collect web statistics. No personal user data is collected.
_gid	11 months	Cookie from Google Inc. to collect web statistics. No personal user data is collected.

CLICK GENE

CLICK BIO

CLICK DIAGNOSTIC

CLICK VLP

VACC-ZERA

STANDARD ASSAYS

SERVICES

ZEBRAFISH ASSAYS

Tailor-made toxicity and efficacy testing in Zebrafish platform.

TAILOR MADE SOLUTIONS

INVESTOR INFO

Ticker “BST”

THE WORKING TEAM

We have a multidisciplinary team ready to tackle new challenges and provide solutions to market needs.

NEWS

News

Accelerate Drug Development Safely: The Power of Dose Range Finding and Zebrafish in Preclinical Research

ZIP SOLUTIONS AND RESEARCHER MIGUEL ÁNGEL MORENO-MATEOS INITIATE SCIENTIFIC ALLIANCE TO BOOST PRECISION GENE EDITING

“Split-Inteins Show Potential for Overcoming Gene Therapy Limitations in Muscular Dystrophy Treatment”

ZIP Solutions and YIMA Announce Strategic Co-Marketing Agreement for Gene Therapy